The U.S. FDA has approved SPRAVATO® (esketamine) as the first monotherapy for adults experiencing treatment-resistant depression. This landmark decision followed a Priority Review and was based on data showing that SPRAVATO® alone successfully met its primary endpoint at 4 weeks, demonstrating rapid and superior improvements in depressive symptoms.
Vero’s thoughts on the news:
This historic approval of SPRAVATO® represents a significant advancement in mental health treatment. With the rapid improvement of depressive symptoms in just four weeks, this therapy promises to revolutionize the approach to treatment-resistant depression. The integration of new technologies in healthcare constantly pushes the boundaries, and SPRAVATO® exemplifies how innovative solutions can address long-standing medical challenges. The tech community would be excited to see how developments like these can be expanded into digital health applications, providing broader access and real-time monitoring of such impactful treatments.
Source: SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression – PR Newswire
Hash: a93d4e208c02a8407ec28aafc2c17bb856af89ddfb2ffde211e8e6381f8a9525
